PMPRB reviewing new NASs in Canada by improvement 2014-2020

The Patented Medicine Prices Review Board reviewed one NAS classified as a substantial improvement in 2020. This statistic depicts the new active substances (NASs) reviewed by the Patented Medicine Prices Review Board in Canada from 2014 to 2020, by therapeutic improvement.

Number of new active substances (NASs) reviewed by PMPRB Canada from 2014 to 2020, by therapeutic improvement

Characteristic	Breakthrough	Substantial Improvement	Moderate Improvement	Slight/no improvement	Other*
2014	1	3	2	19	2
2015	1	1	7	23	6
2016	1	-	7	25	5
2017	3	1	8	22	2
2018	1	0	4	31	4
2019	1	1	3	14	16
2020	1	1	2	17	19

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

2023

More information

Region

Canada

Survey time period

2014 to 2020

Supplementary notes

The year of reporting reflects the year in which the Notice of Compliance was issued rather than the year that the PMPRB conducted its price review.
Medicines reviewed by the PMPRB prior to the implementation of the 2010 Guidelines have been merged as follows: category 2 medicines are included in the Breakthrough category; category 1 medicines are included in the Slight/No Improvement category; and category 3 medicines are included in the Moderate Improvement category.
* New active substances not reported to the PMPRB as of each Annual Report.

Citation formats